non small cell lung cancer

Hong Kong, July 27, 2026 Akeso, Inc. has announced that the first patient has been dosed in the Phase...

PALO ALTO, Calif., June 11, 2026 Guardant Health announced that the U.S. Food and Drug Administration (FDA) has approved...

OXFORD, UK, May 22, 2026 Greywolf Therapeutics announced encouraging clinical results from the Phase 1b portion of its ongoing...

May 31, 2026 – Chicago, Illinois, USA Dizal has unveiled encouraging clinical findings for two innovative non-small cell lung...

CHENGDU, China, May 29, 2026 Kelun-Biotech has presented pivotal Phase II clinical trial results for its next-generation selective RET...

CHICAGO, Ill., May 29, 2026 Johnson & Johnson has announced encouraging long-term results from the Phase 1/1b CHRYSALIS-2 study,...

MAINZ, Germany, May 22, 2026 BioNTech announced new clinical data presentations and pipeline updates from its expanding late-stage oncology...

Hong Kong, April 6, 2026 Promising Results in Immunotherapy-Resistant NSCLC In a significant advancement for lung cancer immunotherapy, Akeso,...